Quarterly ResultMay 15, 2026, 04:29 PM
MiNK Therapeutics Reports Q1 Net Loss $(2.74)M; Going Concern Warning
AI Summary
MiNK Therapeutics reported a net loss of $(2.74) million for Q1 2026, an improvement from $(2.77) million in Q1 2025, with basic and diluted net loss per share improving to $(0.57) from $(0.70). The company disclosed substantial doubt about its ability to continue as a going concern for the next year, despite management's belief that current cash and anticipated funding will be sufficient. During the quarter, MiNK repaid a $5.0 million related party note and raised approximately $3.0 million from equity sales.
Key Highlights
- Net loss for Q1 2026 was $(2.74) million, compared to $(2.77) million in Q1 2025.
- Basic and diluted net loss per share improved to $(0.57) in Q1 2026 from $(0.70) in Q1 2025.
- Cash and cash equivalents stood at $9.5 million as of March 31, 2026.
- Repaid a $5.0 million related party note in January 2026.
- Sold approximately 193,000 common shares for net proceeds of ~$3.0 million in Q1 2026.
- Accumulated deficit reached $159.4 million as of March 31, 2026.
- Net cash used in operating activities increased to $(1.73) million in Q1 2026.
Price Impact
More from INKT